Alnylam, Vir aim for year-end FDA filing to start Covid-19 antiviral drug trial
The companies said Monday they had identified the first candidate for clinical trials, a direct-acting antiviral RNA-interference drug that they plan to develop as an inhaled therapy against the SARS-CoV-2 virus.